Corpus overview


Overview

MeSH Disease

Human Phenotype

Dyspnea (59)

Fever (38)

Cough (34)

Pneumonia (20)

Hypertension (17)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 59
    records per page




    Estimating Risk of Mechanical Ventilation MESHD and Mortality Among Adult TRANS COVID-19 patients Admitted to Mass General Brigham: The VICE and DICE Scores

    Authors: Christopher J Nicholson; Luke Wooster; Haakon H Sigurslid; Rebecca F Li; Wanlin Jiang; Wenjie Tian; Christian Lino Cardenas; Rajeev Malhotra

    doi:10.1101/2020.09.14.20194670 Date: 2020-09-17 Source: medRxiv

    Background: Risk stratification of COVID-19 patients upon hospital admission is key for their successful treatment and efficient utilization of hospital resources. Objective: To evaluate the risk factors associated with ventilation need and mortality. Design, setting and participants: We established a retrospective cohort of COVID-19 patients from Mass General Brigham hospitals. Demographic, clinical, and admission laboratory data were obtained from electronic medical records of patients admitted to hospital with laboratory-confirmed COVID-19 before May 19th, 2020. Using patients admitted to Massachusetts General Hospital (MGH, derivation cohort), multivariable logistic regression analyses were used to construct the Ventilation in COVID Estimator (VICE) and Death MESHD in COVID Estimator (DICE) risk scores. Measurements: The primary outcomes were ventilation status and death MESHD. Results: The entire cohort included 1042 patients (median age TRANS, 64 years; 56.8% male TRANS). The derivation and validation cohorts for the risk scores included 578 and 464 patients, respectively. We found seven factors to be independently predictive for ventilation requirement ( diabetes mellitus HP diabetes mellitus MESHD, dyspnea HP dyspnea MESHD, alanine aminotransferase, troponin, C-reactive protein, neutrophil-lymphocyte ratio, and lactate dehydrogenase), and 10 factors to be predictors of in-hospital mortality ( age TRANS, sex, diabetes mellitus HP diabetes mellitus MESHD, chronic statin use, albumin, C-reactive protein, neutrophil-lymphocyte ratio, mean corpuscular volume, platelet count, and procalcitonin). Using these factors, we constructed the VICE and DICE risk scores, which performed with C-statistics of at least 0.8 in our cohorts. Importantly, the chronic use of a statin was associated with protection against death MESHD due to COVID-19. The VICE and DICE score calculators have been placed on an interactive website freely available to the public (https://covid-calculator.com/). Limitations: One potential limitation is the modest sample sizes in both our derivation and validation cohorts. Conclusion: The risk scores developed in this study may help clinicians more appropriately determine which COVID-19 patients will need to be managed with greater intensity.

    Predicting clinical outcome with phenotypic clusters in COVID-19 pneumonia HP pneumonia MESHD: 2 an analysis of 12,066 hospitalized patients from the Spanish registry SEMI-3 COVID-19.

    Authors: Manuel Rubio-Rivas; Xavier Corbella; Jose Maria Mora-Lujan; Jose Loureiro Amigo; Almudena Lopez Sampalo; Carmen Yera Bergua; Pedro Jesus Esteve Atienzar; Luis Felipe Diez Garcia; Ruth Gonzalez Ferrer; Susana Plaza Canteli; Antia Perez Pineiro; Begona Cortes Rodriguez; Leyre Jorquer Vidal; Ignacio Perez Catalan; Marta Leon Tellez; Jose Angel Martin Oterino; Maria Candelaria Martin Gonzalez; Jose Luis Serrano Carrillo de Albornoz; Eva Garcia Sardon; Jose Nicolas Alcala Pedrajas; Anabel Martin Urda Diez Canseco; Maria Jose Esteban Giner; Pablo Telleria Gomez; Ricardo Gomez Huelgas; Jose Manuel Ramos Rincon; Nina la Cour Freiesleben; Henriette Svarre Nielsen

    doi:10.1101/2020.09.14.20193995 Date: 2020-09-15 Source: medRxiv

    (1) Background: This study aims to identify different clinical phenotypes in COVID-19 88 pneumonia HP pneumonia MESHD using cluster analysis and to assess the prognostic impact among identified clusters in 89 such patients. (2) Methods: Cluster analysis including 11 phenotypic variables was performed in a 90 large cohort of 12,066 COVID-19 patients, collected and followed-up from March 1, to July 31, 2020, 91 from the nationwide Spanish SEMI-COVID-19 Registry. (3) Results: Of the total of 12,066 patients 92 included in the study, most were males TRANS (7,052, 58.5%) and Caucasian (10,635, 89.5%), with a mean 93 age TRANS at diagnosis of 67 years (SD 16). The main pre-admission comorbidities were arterial 94 hypertension HP hypertension MESHD (6,030, 50%), hyperlipidemia HP hyperlipidemia MESHD (4,741, 39.4%) and diabetes mellitus HP diabetes mellitus MESHD (2,309, 19.2%). The 95 average number of days from COVID-19 symptom onset TRANS to hospital admission was 6.7 days (SD 7). 96 The triad of fever HP fever MESHD, cough HP cough MESHD, and dyspnea HP dyspnea MESHD was present almost uniformly in all 4 clinical phenotypes 97 identified by clustering. Cluster C1 (8,737 patients, 72.4%) was the largest, and comprised patients 98 with the triad alone. Cluster C2 (1,196 patients, 9.9%) also presented with ageusia and anosmia MESHD anosmia HP; 99 cluster C3 (880 patients, 7.3%) also had arthromyalgia, headache HP headache MESHD, and sore throat; and cluster C4 100 (1,253 patients, 10.4%) also manifested with diarrhea HP diarrhea MESHD, vomiting HP vomiting MESHD, and abdominal pain HP abdominal pain MESHD. Compared to 101 each other, cluster C1 presented the highest in-hospital mortality (24.1% vs. 4.3% vs. 14.7% vs. 102 18.6%; p<0.001). The multivariate study identified phenotypic clusters as an independent factor for 103 in-hospital death. (4) Conclusion: The present study identified 4 phenotypic clusters in patients with 104 COVID-19 pneumonia HP pneumonia MESHD, which predicted the in-hospital prognosis of clinical outcomes.

    Effect of Arbidol on COVID-19: A Randomized Controlled Trial

    Authors: Marzieh Nojomi; Zainab Yasin; Hossein Keyvani; Mahin Jamshidi Makiani; Maryam Roham; Azadeh Laali; Nasir Dehghan; Mehrnaz Navaei; Mitra Ranjbar

    doi:10.21203/rs.3.rs-78316/v1 Date: 2020-09-15 Source: ResearchSquare

    Background: The treatment of patients with COVID-19 included supportive care to relief the symptoms mainly. Although WHO mentioned there is not any effective treatments for COVID-19, but there is some reporting about the use of some antiviral drugs. The aim of current study is to determine the effect of Arbidol (ARB) on COVID-19 disease. Methods: Using an open label randomized controlled trial, effectiveness of ARB on COVID-19 disease was conducted in a teaching hospital. One hundred eligible patients with diagnosis of Covid-19 recruited in the study and assigned randomly to two groups of either Hydroxychloroquine followed by Kaletra (Lopinavir-ritonavir) or Hydroxychloroquine followed by ARB. The primary outcome was hospitalization duration and clinical improvement 7 days after admission. The criteria of improvement were relief of cough HP, dyspnea HP dyspnea MESHD and fever HP. Time to relieving fever HP fever MESHD was assessed across two groups too. Without any drop out, 100 patients were entered to final analysis with significant level of 0.05. Results: The mean age TRANS of the patients was 56.6 (17.8) and 56.2 (14.8) in ARB and Kaletra groups respectively. Majority of patients were male TRANS across two groups (66% and 54%). The duration of hospitalization in ARB group was less than Kaletra arm significantly (7.2 versus 9.6 days; P=0.02). Time to relief fever HP fever MESHD was almost similar across two groups (2.7 versus 3.1 days in ARB and Kaletra arms respectively). Peripheral oxygen saturation rate was different after seven days of admission across two groups significantly (94% versus 92% in ARB and Kaletra groups respectively) (P=0.02). Based on multiple linear regression analysis, IHD, Na level and oxygen saturation at the time of admission and type of therapy were the independent adjusted variables that determined the duration of hospitalization in patients with COVID-19.Conclusion: Our findings showed that Arbidol, compared to Kaletra, significantly contributes to clinical and laboratory improvements, including peripheral oxygen saturation, requiring ICU admissions, duration of hospitalization, chest CT involvements, WBC, and ESR. We suggest further studies on ARB using larger sample size and multicenter design.Trial registration: IRCT20180725040596N2 on 18 April 2020.

    Insufficient hyperfibrinolysis HP in COVID-19: a systematic review of thrombolysis based on meta-analysis and meta-regression

    Authors: Hong-Long J Ji; Zhenlei Su; Runzhen Zhao; Andrey A Komissarov; Guohua Yi; Shan-Lu Liu; Steven Idell; Michael A Matthay; NAJMA KORI; PETRICK PERIYASAMY; NOR AZIZAN ZAKARIA; AGNI NHIRMAL KUMAR SUGUMAR; NUR EZZATY MOHAMMAD KAZMIN; XIONG KHEE CHEONG; SITI MARIYAM SANIMAN; ILINA ISAHAK; Kevin Wing; Peter Inglesby; Rohini Mathur; Henry Drysdale; Angel YS Wong; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre; Sacha Gnjatic; Noam Harpaz; Silvio Danese; Adeeb Rahman; Nikhil A Kumta; Alessio Aghemo; Francesca Petralia; Harm van Bakel; Adolfo Garcia-Sastre; Saurabh Mehandru

    doi:10.1101/2020.09.07.20190165 Date: 2020-09-09 Source: medRxiv

    Background How aberrant fibrinolysis influences the clinical progression of COVID-19 presents a clinicopathological dilemma challenging intensivists. To investigate whether abnormal fibrinolysis is a culprit or protector or both, we associated elevated plasma SERO D-dimer with clinical variables to identify a panoramic view of the derangements of fibrinolysis that contribute to the pathogenesis of COVID-19 based on studies available in the literature. Methods We performed this systematic review based on both meta-analysis and meta-regression to compute the correlation of D-dimer at admission with clinical features of COVID-19 patients in retrospective studies or case series. We searched the databases until Aug 18, 2020, with no limitations by language. The first hits were screened, data extracted, and analyzed in duplicate. We did the random-effects meta-analyses and meta-regressions (both univariate and multivariate). D-dimer associated clinical variables and potential mechanisms were schematically reasoned and graphed. Findings Our search identified 42 observational, or retrospective, or case series from six countries (n=14,862 patients) with all races and ages TRANS from 1 to 98-year-old. The weighted mean difference of D-dimer was 0.97 g/mL (95% CI 0.65, 1.29) between relatively mild (or healthy control) and severely affected groups with significant publication bias MESHD. Univariate meta-regression identified 58 of 106 clinical variables were associated with plasma SERO D-dimer levels, including 3 demographics, 5 comorbidies, 22 laboratory tests, 18 organ injury biomarkers, 8 severe complications, and 2 outcomes (discharge and death MESHD). Of these, 11 readouts were negatively associated with the level of plasma SERO D-dimer. Further, age TRANS and gender TRANS were confounding factors for the identified D-dimer associated variables. There were 22 variables independently correlated with the D-dimer level, including respiratory rate, dyspnea HP dyspnea MESHD plasma SERO K+, glucose, SpO2, BUN, bilirubin, ALT, AST, systolic blood SERO pressure, and CK. We thus propose that " insufficient hyperfibrinolysis MESHD hyperfibrinolysis HP (fibrinolysis is accelerated but unable to prevent adverse clinical impact for clinical deterioration COVID-19)" as a peculiar mechanism. Interpretation The findings of this meta-analysis- and meta-regression-based systematic review supports elevated D-dimer as an independent predictor for mortality and severe complications. D-dimer-associated clinical variables draw a landscape integrating the aggregate effects of systemically suppressive and locally (i.e., in the lung) hyperactive derangements of fibrinolysis. D-dimer and associated clinical biomarkers and conceptually parameters could be combined for risk stratification, potentially for tracking thrombolytic therapy or alternative interventions.

    Association factors with severe cases and antiviral drug assessment in patients with COVID-19

    Authors: Xiaowei Gong; Xianfeng Guo; Shiwei Kang; Yan Li; Haixiang Gao; Yadong Yuan

    doi:10.21203/rs.3.rs-70914/v1 Date: 2020-09-02 Source: ResearchSquare

    Background Due to the latent onset of novel coronavirus disease MESHD 2019 (COVID-19), it is important to identify patients with increased probabilities for disease progression early in order to implement timely medical strategies. This study aimed to identify the factors associated with severe COVID-19 and evaluate the current antiviral drugs, especially in severe patients.Methods This was a retrospective observational study performed at the No. 7 Hospital of Wuhan (Wuhan, China) with hospitalized patients confirmed with COVID-19 from January 11 to March 13, 2020. Multivariable logistic regression analysis was used to identify the associated factors of severe COVID. Treatment of antivirus drugs were collected and evaluated.Results Of the 550 patients, 292 (53.1%) were female TRANS and 277 (50.4%) were ≥ 60 years old. The most common symptom was fever HP fever MESHD (n = 372, 67.7%), followed by dry cough MESHD cough HP (n = 257, 46.7%), and dyspnea HP dyspnea MESHD (n = 237, 43.1%), and fatigue HP fatigue MESHD (n = 224, 40.7%). Among the severe patients, 20.2% required invasive ventilator support and 18.0% required non-invasive ventilator. The identified risk factors for severe cases were: age ≥ 60 years (odds ratio (OR) = 3.02, 95% confidence interval (CI): 1.13–8.08, P = 0.028), D-dimer > 0.243 µg/ml (OR = 2.734, 95%CI: 1.012–7.387, P = 0.047), and low oxygenation index (OR = 0.984, 95%CI: 0.980–0.989, P < 0.001). In severe cases, the benefits of arbidol alone was 73.3%, which was better than ribavirin (7/17, 41.2%, P = 0.029).Conclusions Age ≥ 60 years, D-dimer > 0.243 µg/ml, and lower oxygenation index were associated with severe cases. Arbidol might provide more clinical benefits in treating patients with severe COVID-19 compared with other antiviral drugs.

    Phosphate levels and pulmonary damage in COVID-19 patients based on CO-RADS scheme: is there any link between parathyroid gland and COVID-19?

    Authors: Farshid Javdani; Shima Parsa; Heshmatollah Shakeri; Naser Hatami; Navid Kalani; Marzieh Haghbeen; Rahim Raufi; Alireza Abbasi; Pouyan Keshavarz; Seyyed Abbas Hashemi; Amin shafiee

    doi:10.1101/2020.08.25.20181453 Date: 2020-08-31 Source: medRxiv

    Background: Preliminary studies of COVID-19 have provided some evidence that electrolyte disturbances may also be present in patients. In this study we aimed to evaluate the role of the arrival electrolytes and symptoms in prediction of Lung damage in CT scan based on the CO-RADS system. Methods: This was a retrospective cross-sectional analytical study. We included patients with laboratory confirmed COVID-19 infection, June 15 to July 7. Patients were included in study if there were no previous history of kidney disease. Demographic, clinical characteristics, laboratory findings, and CO-RADS High-resolution computed tomography (HRCT) of lung report were collected. Univariate logistic regression was employed first to identify the effective, correlated items. All statistics were performed with SPSS version 18.0. Results: In the current study, 36 (20 male TRANS- 16 female TRANS) patients with mean age TRANS of the 54.7 (STD:17.5) years old were studied. Most common symptom at the arrival was the Fever HP (52.8%), followed by Fatigue HP (18%), and dyspnea HP (44.4%). Computed tomography assessment revealed CO-RADS 2 in 4 (11.1%) patients, CO-RADS 3 in 1 (2.8%), CO-RADS 4 in 20 (55.6%), and CO-RADS 5 in 11 (30.6%) patients. In the comparison with the study groups based on the HRCT status (CO-RADS II,III vs. CO-RADS IV,V), patients with severe HRCT damage had significantly lower level of Phosphorus (P<0.05). Univariate logistic regression analysis showed that only one factors was associated with HRCT damage status (Phosphorus, P=0.040). Phosphorus upper than 4.5 was associated with better HRCT results with OR ratio of 3.71 (X2(1)=5.69; p=0.017). Conclusion: Our study illustrates that higher phosphate levels may be associated with better CT scan of lung outcomes in COVID-19; while hypophosphatemia HP is associated with severe lung injuries. This could help clinicians to manage hospitalized patients and may link the COVID-19 and parathyroid gland.

    Clinical Characteristics, Comorbidities, Initial Management and Outcome of COVID-19 Infected Patients Admitted to Intensive Care Unit in Somalia: A National Retrospective Study.

    Authors: Mohamed Farah Yusuf Mohamud; Abdullahi Said Hashi; Abdikarim Hussein Mohamed; Ali Mohamed Yusuf; Ibrahim Hussein Ali; Mohamed Abdi Ahmed

    doi:10.21203/rs.3.rs-66767/v1 Date: 2020-08-27 Source: ResearchSquare

    Purpose: To investigate the clinical characteristics, morbidities, management, and outcomes of COVID-19 Infected patients admitted to the intensive care unit (ICU) in Somalia.Material MESHD and methods: We conducted a retrospective observational study of laboratory 60 confirmed patients with severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) admitted to an ICU from March 28, to May 28, 2020.The sociodemographic characteristics, comorbidities, exposure history, clinical manifestations (symptoms and signs), laboratory findings, treatment, and outcomes were collected from medical records.Results: Most of the patients admitted to ICU were men over 59 years of age TRANS, and nearly half had diabetes MESHD followed by hypertension HP hypertension MESHD chronic kidney disease HP and asthma HP asthma MESHD. The most clinical presentations were dyspnea HP dyspnea MESHD (91.2%), Fever HP Fever MESHD (81.1%), (68.75%), Fatigue HP and myalgia HP myalgia MESHD (25%), and Altered level of conscious (16.6%). Among 48 patients admitted to the ICU, about 24 (50%) patients had required endotracheal intubation and mechanical ventilation, and 11(29.9%) patients needed noninvasive ventilation, while 13(27.08%) patients treated with high-flow oxygen therapy >15 L/min (Table 3). Corticosteroids were administered to most patients (85.4%), while 77.1% of the patients received inhaled bronchodilators and morethan half of the patients administered antibiotics. 58.3% of the patients had received Oseltamivir, while 22.9% received Vasopressors.Conclusion This study represents the first description of critically ill MESHD patients infected with SARS-CoV-2 admitted to ICU in Somalia. The study identified that elder age TRANS, male TRANS gender TRANS, and diabetic MESHD and hypertensive MESHD comorbidities as independent risk factors of poor outcomes for patients admitted to the ICU (p<0.005).

    Post-discharge health status and symptoms in patients with severe COVID-19

    Authors: Himali Weerahandi; Katherine A. Hochman; Emma Simon; Caroline Blaum; Joshua Chodosh; Emily Duan; Kira Garry; Tamara Kahan; Savannah Karmen-Tuohy; Hannah Karpel; Felicia Mendoza; Alexander M. Prete; Lindsey Quintana; Jennifer Rutishauser; Leticia Santos Martinez; Kanan Shah; Sneha Sharma; Elias Simon; Ana Stirniman; Leora Horwitz; Girish N Nadkarni; Fei Wang; Benjamin S Glicksberg; Laura J. Scott; Karen L. Mohlke; Kerrin S. Small

    doi:10.1101/2020.08.11.20172742 Date: 2020-08-14 Source: medRxiv

    Background: Little is known about long-term recovery from severe COVID-19 disease. Here, we characterize overall health, physical health and mental health of patients one month after discharge for severe COVID-19. Methods: This was a prospective single health system observational cohort study of patients [≥]18 years hospitalized with laboratory-confirmed COVID-19 disease who required at least 6 liters of oxygen during admission, had intact baseline cognitive and functional status and were discharged alive. Participants were enrolled between 30 and 40 days after discharge. Outcomes were elicited through validated survey instruments: the PROMIS Dyspnea HP Dyspnea MESHD Characteristics and PROMIS Global Health-10. Results: A total of 161 patients (40.6% of eligible) were enrolled; 152 (38.3%) completed the survey. Median age TRANS was 62 years (interquartile range [IQR], 50-67); 57 (37%) were female TRANS. Overall, 113/152 (74%) participants reported shortness of breath MESHD within the prior week (median score 3 out of 10 [IQR 0-5]), vs. 47/152 (31%) pre-COVID-19 infection (0, IQR 0-1), p<0.001. Participants also rated their physical health and mental health as worse in their post-COVID state (43.8, standard deviation 9.3; mental health 47.3, SD 9.3) compared to their pre-COVID state, (54.3, SD 9.3; 54.3, SD 7.8, respectively), both p <0.001. A total of 52/148 (35.1%) patients without pre-COVID oxygen requirements needed home oxygen after hospital discharge; 20/148 (13.5%) reported still using oxygen at time of survey. Conclusions: Patients with severe COVID-19 disease typically experience sequelae affecting their respiratory status, physical health and mental health for at least several weeks after hospital discharge.

    Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease MESHD 2019: A Systematic Review and Meta-Analysis

    Authors: Vignesh Chidambaram; Nyan Lynn Tun; Waqas Haque; Marie Gilbert Majella; Ranjith Kumar Sivakumar; Amudha Kumar; Angela Ting-Wei Hsu; Izza Ishak; Aqsha Nur; Samuel Ayeh; Emmanuella Salia; Ahsan Zil-E-Ali; Muhammad Saeed; Ayu Sarena; Bhavna Seth; Muzzammil Ahmadzada; Eman Haque; Pranita Neupane; Kuang-Heng Wang; Tzu-Miao Pu; Syed Ali; Muhammad Arshad; Lin Wang; Sheriza Baksh; Petros Karakousis; Panagis Galiatsatos

    doi:10.1101/2020.08.07.20166868 Date: 2020-08-13 Source: medRxiv

    Background: Understanding the factors associated with disease severity and mortality in Coronavirus disease MESHD (COVID19) is imperative to effectively triage patients. We performed a systematic review to determine the demographic, clinical, laboratory and radiological factors associated with severity and mortality in COVID-19. Methods: We searched PubMed, Embase and WHO database for English language articles from inception until May 8, 2020. We included Observational studies with direct comparison of clinical characteristics between a) patients who died and those who survived or b) patients with severe disease and those without severe disease. Data extraction and quality assessment were performed by two authors independently. Results: Among 15680 articles from the literature search, 109 articles were included in the analysis. The risk of mortality was higher in patients with increasing age TRANS, male TRANS gender TRANS (RR 1.45; 95%CI 1.23,1.71), dyspnea HP dyspnea MESHD (RR 2.55; 95%CI 1.88,2.46), diabetes MESHD (RR 1.59; 95%CI 1.41,1.78), hypertension HP hypertension MESHD (RR 1.90; 95%CI 1.69,2.15). Congestive heart failure HP Congestive heart failure MESHD (OR 4.76; 95%CI 1.34,16.97), hilar lymphadenopathy HP lymphadenopathy MESHD (OR 8.34; 95%CI 2.57,27.08), bilateral lung involvement (OR 4.86; 95%CI 3.19,7.39) and reticular pattern (OR 5.54; 95%CI 1.24,24.67) were associated with severe disease. Clinically relevant cut-offs for leukocytosis HP leukocytosis MESHD(>10.0 x109/L), lymphopenia HP lymphopenia MESHD(< 1.1 x109/L), elevated C-reactive protein(>100mg/L), LDH(>250U/L) and D-dimer(>1mg/L) had higher odds of severe disease and greater risk of mortality. Conclusion: Knowledge of the factors associated of disease severity and mortality identified in our study may assist in clinical decision-making and critical-care resource allocation for patients with COVID-19.

    Retropharyngeal Abscess MESHD Abscess HP in an adult TRANS with Pneumonia HP during COVID-19 Outbreak in China

    Authors: Tianyu Wang; Haibin Liu; Caiquan Liang; Hang Zhang; Jianchun Liao; Huanhai Liu

    doi:10.21203/rs.3.rs-58631/v1 Date: 2020-08-13 Source: ResearchSquare

    Background: Retropharyngeal abscesses HP are rarely reported in adults TRANS and occur mostly in patients with immunocompromise or as a foreign body complication. Admittedly, the treatment of retropharyngeal abscesses HP frequently involves surgical drainage to achieve the best results. However, when retropharyngeal abscesses HP occurred in a highly suspected patient with COVID-19, the managements and treatments should be caution in order to prevent the spread of the virus. Case presentation: On Feb. 13, a 40-year-old male TRANS with retropharyngeal abscesses HP turned to our department complaining dyspnea HP dyspnea MESHD and dysphagia HP dysphagia MESHD. In addition, his chest CT scan shows a suspected COVID-19 infection MESHD, thus making out Multiple Disciplinary Team (MDT) determine to perform percutaneous drainage and catheterization through left anterior cervical approach under the guidance of B-ultrasound. Finally, the patient recovered and was discharged from the hospital on Feb. 27 after 14 days of isolation. There was no recurrence after half a year follow-up. Conclusions: By presenting this case, we aim at raising awareness of different surgical drainage methods and summarizing our experience in the management of retropharyngeal abscesses HP during the outbreak of COVID-19. 

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.